Stocky turns companies like Candel Therapeutics, Inc. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. CADL's Value Compounder Score of 16/100 reflects a biotech with limited financial traction, while Leadership Alignment (55/100) lacks founder-CEO unity or meaningful insider conviction. The critical vulnerability: FDA approval of core candidates aglatimagene and linoserpaturev remains unresolved, creating existential execution risk that outweighs any pipeline upside. Clinical trial success is binary and unproven.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Candel Therapeutics, Inc.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 28/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Candel Therapeutics, Inc. (CADL) at 28/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. CADL's Value Compounder Score of 16/100 reflects a biotech with limited financial traction, while Leadership Alignment (55/100) lacks founder-CEO unity or meaningful insider conviction. The critical vulnerability: FDA approval of
CADL's current Stocky Verdict is 28/100, placing it in the "Avoid" band. This composite combines a 4/100 Compounder score, 55/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Candel Therapeutics, Inc. yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Candel Therapeutics, Inc. scores 55/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Candel Therapeutics, Inc.'s Vulnerability Profile scores 50/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Candel Therapeutics, Inc..
Sign up free and unlock the full analysis on CADL — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for CADL in the app.
